Resistance to Ibrutinib

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

In the mHSPC setting, treatment approaches are rapidly evolving, sparking ongoing debate among clinicians about the efficacy of doublet vs triplet therapy.

TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.